Overall, the global botulinum toxin A market was valued at nearly $6.6 billion in 2022. This is expected to increase over the forecast period at a CAGR of 6.5% to reach nearly $10.2 billion.

The full report suite on the global market for botulinum toxin A (botox A) includes aesthetic and therapeutic segments. The total botulinum toxin A procedure volume is reported on a regional and country level.

MARKET DATA INCLUDED

• Unit Sales, Average Selling Prices, Market Size & Growth Trends
• Procedure Numbers
• COVID-19 Impact Analysis
• Market Drivers & Limiters
• Market Forecasts Until 2029, and Historical Data to 2019
• Recent Mergers & Acquisitions
• Company Profiles and Product Portfolios
• Leading Competitors

GLOBAL BOTULINUM TOXIN A MARKET INSIGHTS

The growth in the global botulinum toxin A market is primarily driven by the increasing popularity and acceptance of minimally invasive cosmetic procedures, such as injectables. Injectables are flourishing as patients seek affordable treatments with little to no downtime. Preventative treatments show that it is easier (and less expensive) to treat wrinkles before they arise, whereas deeply etched lines may require more intensive treatments.

GLOBAL BOTULINUM TOXIN A MARKET SHARE INSIGHTS

The global botulinum toxin A market was dominated by Allergan Aesthetics, Galderma, Merz Aesthetics and Johnson & Johnson. Collectively, these companies accounted for over half of the overall market value.Allergan Aesthetics, an AbbVie company, led the global botulinum toxin A market in 2022. Allergan offers its BOTOX® solution, an onabotulinum toxin A injection designed to treat glabellar frown lines, periorbital lines (crow’s feet) and forehead lines in adults. In February 2021, AbbVie received the approval from the U.S. Food and Drug Administration (FDA) for the treatment of detrusor overactivity associated with a neurological condition in certain pediatric patients.

MARKET SEGMENTATION SUMMARY

• Aesthetic Botulinum Toxin A Market
• Therapeutic Botulinum Toxin A Market

Research Scope Summary

WHY CHOOSE IDATA?

• Experts Only – iData has been around for over 17 years and is the trusted source of intelligence, and data-driven insights for key industry players. We are made up of specialists with a sole focus on medical devices, dental devices and pharmaceuticals. Our research and consulting field of endeavor never strays from the medical device industry and, because of this, we are the number one choice for leading companies in this field.
• Global Coverage – iData’s unique methodology, and its expansion to over 70 countries world-wide, has made it one of the most viable sources of intelligence for global companies along with those who plan to expand their portfolio beyond the confines of their own country. Providing procedural data at the country level is another testimony to the trusted global coverage we provide.
• Attention to Detail – It’s our attention to small details, scheduling of timelines, and keen project management that makes us stand out from the rest. We are creative, and our reports include metrics such as procedure numbers, ASPs, and SKU-level insights that are not found elsewhere.
• Pricing – When comparing like-with-like, iData’s prices are not only extremely competitive but also the most cost-effective. We strive for success and want the same for our clients. With the level of detail incorporated into each report alongside the extensive segmentation provided, no other report compares at our price point.

FREE Sample Report